
Berlin: With the entire world watching closely about the new strain of coronavirus, the co-founder of BioNTech said Tuesday it was "highly likely" that its vaccine against the coronavirus works against the mutated strain detected in Britain, but it could also adapt the vaccine if necessary in six weeks.
"Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant," said Ugur Sahin.
But if needed, "in principle the beauty of the messenger technology is that we can directly start to engineer a vaccine which completely mimics this new mutation -- we could be able to provide a new vaccine technically within six weeks."
The variant detected in Britain has nine mutations, rather than just one as is usually common, he said.
Nevertheless, he voiced confidence that the vaccine developed with Pfizer would be efficient because it "contains more than 1,000 amino acids, and only nine of them have changed, so that means 99 percent of the protein is still the same".
He said tests are being run on the variant, with results expected in two weeks.
"We have scientific confidence that the vaccine might protect but we will only know it if the experiment is done... we will publish the data as soon as possible," he added.
(With inputs from agency)
Check the Breaking News Today and Latest News from across India and around the world. Stay updated with the latest World News and global developments from politics to economy and current affairs. Get in-depth coverage of China News, Europe News, Pakistan News, and South Asia News, along with top headlines from the UK and US. Follow expert analysis, international trends, and breaking updates from around the globe. Download the Asianet News Official App from the Android Play Store and iPhone App Store for accurate and timely news updates anytime, anywhere.